Transforming Allergy Treatment

Media Centre

All News for 2006

December 07.2006

Promising data from oral allergy vaccine study. Preliminary results show potential for a rapid action, injection-free allergy treatment

October 13.2006

Positive outcome from Pollinex® Quattro Ragweed dose ranging study and succesfull completion of phase II programme

September 12.2006

Allergy Therapeutics plc Primliminary Statement (for the year ended 30 June 2006). Significant progress in clinical development programmes Health Canada accepts Pollinex® Quattro Ragweed for submissio

August 02.2006

Response to Government Review of services for allergy

$11$

July 19.2006

Successful review meeting with Japan’s Pharmaceutical and Medical Devices Agency Japan development of Pollinex® Quattro progressed

July 04.2006

Successful end of Phase II meeting with FDA - Allergy Therapeutics to proceed with Phase III development of Pollinex® Quattro.

June 21.2006

Commencement of long term follow up study for Pollinex® Quattro Ragweed – R205 Quality of Life Information – R204

April 28.2006

Positive outcome of pivotal Pollinex(R) Quattro Ragweed study - R204

April 10.2006

Placing of 19,000,000 new Ordinary Shares of 0.1p each at 100p per Share

Allergy Vaccination Receives a Positive Reaction

March 13.2006

Allergy Therapeutics plc announces commencement of Sublingual allergy vaccine trial - MPL103

March 06.2006

Allergy Therapeutics plc announces the completion of Pollinex® Quattro Phase II Grass programme and positive outcome of study G203

March 01.2006

28 February 2006 Allergy Therapeutics plc Notification of Results